- $13.45bn
- $12.32bn
- $3.87bn
- 71
- 14
- 89
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 665 | 823 | 1,705 | 2,731 | 3,865 |
Cost of Revenue | |||||
Gross Profit | 62.3 | 140 | 314 | 511 | 834 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 878 | 1,043 | 1,983 | 3,115 | 4,152 |
Operating Profit | -213 | -220 | -278 | -384 | -287 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -213 | -248 | -490 | -277 | -244 |
Provision for Income Taxes | |||||
Net Income After Taxes | -209 | -248 | -487 | -275 | -246 |
Net Income Before Extraordinary Items | |||||
Net Income | -209 | -248 | -487 | -275 | -246 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -209 | -249 | -487 | -275 | -246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.418 | -0.482 | -0.894 | -0.535 | -0.436 |
Dividends per Share |